FDA approves biosimilar SIMLANDI by Alvotech and Teva Pharmaceuticals
Alvotech and Teva Pharmaceuticals have achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of SIMLANDI (adalimumab-ryvk) injection. This approval positions SIMLANDI as an interchangeable biosimilar to Humira, a leading treatment for various arthritis and inflammatory conditions. The approval covers a wide range of conditions, including adult rheumatoid arthritis, juvenile idiopathic […]